Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance

Siobhan Briody, Mona Boules, Alfredo Oliveros, Irfan Fauq, Elliott Richelson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

NT69L is a neurotensin receptor agonist with antipsychotic-like activity. NT69L blocks apomorphine-induced climbing in rats with no effect on stereotypic behavior, attenuates d-amphetamine-induced hyperactivity, and blocks pharmacologically induced disruption of prepulse inhibition (PPI) of the startle response. Repeated administration of NT69L results in tolerance to some, but not to all of its effects. Because schizophrenic patients require long-term treatment, chronic (21-day) administration of NT69L was tested in PPI with comparisons to chronic haloperidol and clozapine treatment. Sprague-Dawley rats received acute or 21 daily, subcutaneous injections of NT69L (1.0 mg/kg). On days 1 and 21 the NT69L injection was followed 30 min later by treatment with either saline; the dopamine agonist, d-amphetamine (5.0 mg/kg); or the serotonin 5-HT2A psychotomimetic receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] DOI (0.5 mg/kg). Experiments were repeated with either haloperidol (1 mg/kg) or clozapine (20 mg/kg) in place of NT69L. Acute injection of NT69L significantly blocked d-amphetamine and DOI disruption of PPI. As with the acute injection, 21 daily administrations of NT69L also blocked d-amphetamine- and DOI-induced disruption of PPI. The data show that animals do not develop tolerance to the antipsychotic-like effects of NT69L when tested in the PPI of the startle response. The persistent efficacy of NT69L with chronic treatment provides further support for the therapeutic use of neurotensin (NT) agonists to treat schizophrenia and possibly other disorders that are characterized by PPI deficits. The modulatory role of NT69L on the dopaminergic and serotonergic neurotransmission systems both of which are implicated in the pathophysiology of schizophrenia is discussed.

Original languageEnglish (US)
Pages (from-to)118-124
Number of pages7
JournalBehavioural Brain Research
Volume207
Issue number1
DOIs
StatePublished - Feb 11 2010

Fingerprint

Pharmaceutical Preparations
Dextroamphetamine
Startle Reflex
Clozapine
Haloperidol
Antipsychotic Agents
Injections
Prepulse Inhibition
neurotensin 69L
Schizophrenia
Neurotensin Receptors
Serotonin 5-HT2 Receptor Agonists
Neurotensin
Apomorphine
Dopamine Agonists
Therapeutic Uses
Subcutaneous Injections
Therapeutics
Synaptic Transmission
Sprague Dawley Rats

Keywords

  • Clozapine
  • Haloperidol
  • Neurotensin
  • Prepulse inhibition
  • Tolerance

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. / Briody, Siobhan; Boules, Mona; Oliveros, Alfredo; Fauq, Irfan; Richelson, Elliott.

In: Behavioural Brain Research, Vol. 207, No. 1, 11.02.2010, p. 118-124.

Research output: Contribution to journalArticle

Briody, Siobhan ; Boules, Mona ; Oliveros, Alfredo ; Fauq, Irfan ; Richelson, Elliott. / Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. In: Behavioural Brain Research. 2010 ; Vol. 207, No. 1. pp. 118-124.
@article{787e905a5ff24ac4bc06c0fa22953527,
title = "Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance",
abstract = "NT69L is a neurotensin receptor agonist with antipsychotic-like activity. NT69L blocks apomorphine-induced climbing in rats with no effect on stereotypic behavior, attenuates d-amphetamine-induced hyperactivity, and blocks pharmacologically induced disruption of prepulse inhibition (PPI) of the startle response. Repeated administration of NT69L results in tolerance to some, but not to all of its effects. Because schizophrenic patients require long-term treatment, chronic (21-day) administration of NT69L was tested in PPI with comparisons to chronic haloperidol and clozapine treatment. Sprague-Dawley rats received acute or 21 daily, subcutaneous injections of NT69L (1.0 mg/kg). On days 1 and 21 the NT69L injection was followed 30 min later by treatment with either saline; the dopamine agonist, d-amphetamine (5.0 mg/kg); or the serotonin 5-HT2A psychotomimetic receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] DOI (0.5 mg/kg). Experiments were repeated with either haloperidol (1 mg/kg) or clozapine (20 mg/kg) in place of NT69L. Acute injection of NT69L significantly blocked d-amphetamine and DOI disruption of PPI. As with the acute injection, 21 daily administrations of NT69L also blocked d-amphetamine- and DOI-induced disruption of PPI. The data show that animals do not develop tolerance to the antipsychotic-like effects of NT69L when tested in the PPI of the startle response. The persistent efficacy of NT69L with chronic treatment provides further support for the therapeutic use of neurotensin (NT) agonists to treat schizophrenia and possibly other disorders that are characterized by PPI deficits. The modulatory role of NT69L on the dopaminergic and serotonergic neurotransmission systems both of which are implicated in the pathophysiology of schizophrenia is discussed.",
keywords = "Clozapine, Haloperidol, Neurotensin, Prepulse inhibition, Tolerance",
author = "Siobhan Briody and Mona Boules and Alfredo Oliveros and Irfan Fauq and Elliott Richelson",
year = "2010",
month = "2",
day = "11",
doi = "10.1016/j.bbr.2009.09.044",
language = "English (US)",
volume = "207",
pages = "118--124",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance

AU - Briody, Siobhan

AU - Boules, Mona

AU - Oliveros, Alfredo

AU - Fauq, Irfan

AU - Richelson, Elliott

PY - 2010/2/11

Y1 - 2010/2/11

N2 - NT69L is a neurotensin receptor agonist with antipsychotic-like activity. NT69L blocks apomorphine-induced climbing in rats with no effect on stereotypic behavior, attenuates d-amphetamine-induced hyperactivity, and blocks pharmacologically induced disruption of prepulse inhibition (PPI) of the startle response. Repeated administration of NT69L results in tolerance to some, but not to all of its effects. Because schizophrenic patients require long-term treatment, chronic (21-day) administration of NT69L was tested in PPI with comparisons to chronic haloperidol and clozapine treatment. Sprague-Dawley rats received acute or 21 daily, subcutaneous injections of NT69L (1.0 mg/kg). On days 1 and 21 the NT69L injection was followed 30 min later by treatment with either saline; the dopamine agonist, d-amphetamine (5.0 mg/kg); or the serotonin 5-HT2A psychotomimetic receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] DOI (0.5 mg/kg). Experiments were repeated with either haloperidol (1 mg/kg) or clozapine (20 mg/kg) in place of NT69L. Acute injection of NT69L significantly blocked d-amphetamine and DOI disruption of PPI. As with the acute injection, 21 daily administrations of NT69L also blocked d-amphetamine- and DOI-induced disruption of PPI. The data show that animals do not develop tolerance to the antipsychotic-like effects of NT69L when tested in the PPI of the startle response. The persistent efficacy of NT69L with chronic treatment provides further support for the therapeutic use of neurotensin (NT) agonists to treat schizophrenia and possibly other disorders that are characterized by PPI deficits. The modulatory role of NT69L on the dopaminergic and serotonergic neurotransmission systems both of which are implicated in the pathophysiology of schizophrenia is discussed.

AB - NT69L is a neurotensin receptor agonist with antipsychotic-like activity. NT69L blocks apomorphine-induced climbing in rats with no effect on stereotypic behavior, attenuates d-amphetamine-induced hyperactivity, and blocks pharmacologically induced disruption of prepulse inhibition (PPI) of the startle response. Repeated administration of NT69L results in tolerance to some, but not to all of its effects. Because schizophrenic patients require long-term treatment, chronic (21-day) administration of NT69L was tested in PPI with comparisons to chronic haloperidol and clozapine treatment. Sprague-Dawley rats received acute or 21 daily, subcutaneous injections of NT69L (1.0 mg/kg). On days 1 and 21 the NT69L injection was followed 30 min later by treatment with either saline; the dopamine agonist, d-amphetamine (5.0 mg/kg); or the serotonin 5-HT2A psychotomimetic receptor agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane] DOI (0.5 mg/kg). Experiments were repeated with either haloperidol (1 mg/kg) or clozapine (20 mg/kg) in place of NT69L. Acute injection of NT69L significantly blocked d-amphetamine and DOI disruption of PPI. As with the acute injection, 21 daily administrations of NT69L also blocked d-amphetamine- and DOI-induced disruption of PPI. The data show that animals do not develop tolerance to the antipsychotic-like effects of NT69L when tested in the PPI of the startle response. The persistent efficacy of NT69L with chronic treatment provides further support for the therapeutic use of neurotensin (NT) agonists to treat schizophrenia and possibly other disorders that are characterized by PPI deficits. The modulatory role of NT69L on the dopaminergic and serotonergic neurotransmission systems both of which are implicated in the pathophysiology of schizophrenia is discussed.

KW - Clozapine

KW - Haloperidol

KW - Neurotensin

KW - Prepulse inhibition

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=70649101230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649101230&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2009.09.044

DO - 10.1016/j.bbr.2009.09.044

M3 - Article

C2 - 19800922

AN - SCOPUS:70649101230

VL - 207

SP - 118

EP - 124

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 1

ER -